Navigation Links
Studies Investigate New Methodologies to Improve Recovery and Survival Strategies for Patients Undergoing Hematopoietic Cell Transplantation
Date:12/10/2011

ffect. Recognizing this challenge, researchers sought to create a new method to suppress GVHD without compromising the GVT effect by using genetically engineered donor T-cells that over-express a protein known to induce cell death in an effort to specifically attack cancer cells.

The protein, Tumor Necrosis Factor (TNF)-Related Apoptosis-Inducing Ligand, or TRAIL, is naturally expressed on some immune cells in the body. TRAIL targets tumor cells and keeps them from multiplying and spreading by interacting with death receptor molecules, which are highly expressed on the surface of tumor cells, making them more susceptible to therapeutic targeting using TRAIL.

To evaluate the effect of genetically engineered donor T-cells over-expressing TRAIL (TRAIL+) on GVHD and GVT, investigators from Memorial Sloan-Kettering Cancer Center performed HCT using TRAIL+ donor T-cells versus control donor T-cells in experimental mouse models with cancerous tumors. Mice that received TRAIL+ donor T-cells displayed significantly higher survival rates, indicating greater antitumor activity than in those treated with control donor T-cells. The researchers also used donor TRAIL+ progenitor T-cell with autologous (stem cells from the patient) HCT in tumor-bearing mice and found a significantly higher anti-tumor effect compared with controls. In addition to enhanced GVT effect, the transplant recipients treated with TRAIL+ T-cells experienced significantly less severe GVHD. Researchers further found that the immune cells, which trigger GVHD, also express TRAIL-sensitive death receptors, and TRAIL+ T-cells can suppress GVHD by targeting these cells.

"Our data show that donor T-cells over-expressing TRAIL can suppress GVHD while simultaneously enhancing the GVT effects. We hope this approach will provide fresh insights into separating cancer cell killing from indiscriminate killing of normal tissues," said Arnab Ghosh, MD, PhD, lead author and a Research Scholar in the lab
'/>"/>

SOURCE American Society of Hematology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Bayers Drospirenone-containing Combination Oral Contraceptives: FDA Advisory Committees Affirm Positive Benefit-risk Profile and Recommend an Update of Labels to Reflect Information From Available Studies
2. Genomic Health Announces Presentation of Sixteen Oncotype DX Studies at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
3. Montage Announces Three More Hospitals Implement Their On-Demand Search and Data Mining Technology for Radiology Studies
4. Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types
5. Isis Initiates Phase 1 Studies with Isis-GCGRRx and Isis-GCCRRx to Treat Type 2 Diabetes
6. Data From Phase 2 Clinical Studies of Telotristat Etiprate in Patients With Carcinoid Syndrome to be Presented at North American Neuroendocrine Tumor Society Meeting
7. New Clinical Studies Presented at the American Society of Anesthesiologists Annual Meeting Show Benefits of Masimo Noninvasive Technologies: SpHb, PVI, RRa, and SEDLine
8. Inovio Pharmaceuticals and VGX International to Advance Therapeutic Hepatitis C and Hepatitis B Synthetic Vaccines into Clinical Studies
9. Managing Bioequivalence Studies to Optimize the Quality, Cost, and Speed of Generics Manufacturing
10. FDA Seeks Comment on Proposed Guidelines for High-Quality Clinical Studies
11. Urgent® PC Clinical Studies Results Scheduled for Presentation at International Continence Society
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... -- Levi & Korsinsky announces that a class action ... Court for the District of Nevada ... Inc. ("Galectin" or the "Company") (NasdaqCM: GALT) securities between ... For more information, click here: http://zlk.9nl.com/galectin-therapeutics-galt . ... the Company violated federal securities laws by issuing false ...
(Date:8/28/2014)... 2014 According to a new ... (RFID) Market (Tags, Readers, Middleware, Printers and Cabinets) - ... 2014 - 2020" the global radiofrequency identification (RFID) market ... is expected to grow at a CAGR of 13.9% ... of USD 5.3 billion in 2020. Browse ...
(Date:8/28/2014)... YORK , Aug. 28, 2014 ... new market research report is available ... Multiforme Therapeutics in Asia-Pacific Markets to ... High Unmet Need in Newly Diagnosed ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 2Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 3Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 4Radiofrequency Identification (RFID) Market in Healthcare is Expected to Reach USD 5.3 Billion Globally by 2020: Transparency Market Research 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9
... HERZELIYA, Israel, September 30 ... in an investment round led by 7 Health,Ventures. ... in the round as well. , ... optical guidance systems used,in Computer Tomography (CT), fluoroscopy ...
... Ill., Sept. 30 Life Spine announced today that ... 510(k) marketing approval to the SENTINEL Occipito-Cervico-Thoracic (OCT) System. ... and promotes fusion from the occiput to thoracic spine, ... procedures. Polyaxial screws are available in multiple diameters and ...
Cached Medicine Technology:
(Date:8/28/2014)... (PRWEB) August 29, 2014 ... brings pharmaceutical industry precision to the development and ... approval for its primary location in Sarasota County. ... decisively with a total commitment to attracting new ... to creating," says David Wright, President and CEO ...
(Date:8/28/2014)... Arizona (PRWEB) August 28, 2014 When ... and long-time friend of Mark Brnovich, was asked ... the Republican nomination for the Attorney General seat in ... He quickly gathered the support of Cardinal Hall of ... Arizona Cardinals Derek Kennard and Mark Walczak. Green, Kennard ...
(Date:8/28/2014)... 2014 New Energy Works Timberframe plans ... around the country to Log & Timber Home Shows ... The New Energy Works team will invite the shows’ ... and build expertise, project images, and their new 2015 ... Energy Works’ Mid-West Representative, will present “A fun-fill odyssey: ...
(Date:8/28/2014)... A 42-year-old investment banker arrives at the emergency ... tremor. He drinks alcohol every dayoften at business ... his health, he decided to quit drinking and ... to emergency. , It,s a common scenario in ... excessive alcohol consumption and develops withdrawal. , Withdrawal ...
(Date:8/28/2014)... On August 21, the Mesothelioma Applied ... featuring the organization’s audited financial information, as well as ... the report, in 2013, the Meso Foundation spent 86 ... on fundraising and administration. , “The Meso Foundation ... Foundation’s chief executive officer, Melinda Kotzian. , “As a ...
Breaking Medicine News(10 mins):Health News:Sarasota County Approves Zoning for Leading Medical Cannabis Firm AltMed 2Health News:Pro Player Health Alliance Back in the Political Arena 2Health News:Pro Player Health Alliance Back in the Political Arena 3Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 2Health News:New Energy Works Timberframers Prepares to Exhibit Timber Framing at Autumn Trade Shows 3Health News:Real tremors, or drug-seeking patient? New app can tell 2Health News:Real tremors, or drug-seeking patient? New app can tell 3Health News:Mesothelioma Applied Research Foundation’s Annual Report 2013 Release 2
... 2008) -- Pancreatic cancer is one of the ... in a major step forward, researchers at NewYork-Presbyterian ... radiation therapy prior to surgery nearly doubles survival ... "Patients who received pre-surgical (neoadjuvant) radiation had almost ...
... unmatched in its ability to deliver a ... across clinical settings to aid decision-making and ... announced that it earned two of Healthcare ... four of the five categories, ICA was ...
... Consumption and Kidney Cancer , There is no ... kidney cancer, according to a pooled analysis of prospective ... increasing worldwide, but the cause of the increase remains ... to an association between consumption of fat, protein, and ...
... , HARRISBURG, Pa., Nov. 25 In ... School District, the Pennsylvania Department of Health held vaccination clinics ... School on Nov. 19 and Nov. 24. , ... given to approximately 560 parents, students, and staff after an ...
... those with poor glucose control likely to have artery disease ... earlier research, a new study has identified a genetic ... in type 2 diabetes patients with poor sugar glucose (glycemic) ... on a genetic chromosome known as chromosome 9p21 are ...
... to blame, study concludes , , TUESDAY, Nov. 25 (HealthDay News) ... cancer for older women, according to a new study that ... their mammogram habits. , The weight itself is to blame ... who are above their healthy weight have higher levels of ...
Cached Medicine News:Health News:Radiation before surgery improves pancreatic cancer outcomes 2Health News:Radiation before surgery improves pancreatic cancer outcomes 3Health News: Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories 2Health News: Informatics Corporation of America Takes 2008 Healthcare IT Summit by Storm, Winning Two of Five Award Categories 3Health News:Also in the Nov. 25 JNCI 2Health News:Also in the Nov. 25 JNCI 3Health News:Also in the Nov. 25 JNCI 4Health News:Chromosome Linked to Diabetics' Heart Risks 2Health News:Weight Boosts Older Women's Breast Cancer Risk 2Health News:Weight Boosts Older Women's Breast Cancer Risk 3
Assay for Anti-HTLV-I and Anti-HTLV-II...
... assays for the blood screening market. We have ... in contract funding from the National Heart, Lung, ... develop the Procleix WNV Assay. This assay was ... under an Investigational New Drug Application (IND) on ...
Test for Anti-HBc for use on the Abbott Prism...
... BenchMark XT® the only fully automated ... you need to expand your test ... your slide turnaround time. All with ... how to use the BenchMark XT® ...
Medicine Products: